Amesite Business Summary

Amesite Inc. (AMST) is an AI-driven technology company that generates revenue through a multi-tiered subscription model, primarily targeting the $470 billion U.S. post-acute healthcare market. Its business segments are anchored by the NurseMagic™ platform, which includes a flagship AI-powered documentation app and a modular, AI-native Electronic Medical Record (EMR) system launched in early 2026. Revenue is driven by B2C individual subscriptions and B2B enterprise contracts, the latter of which utilizes a census-based pricing model aligned with patient volumes. This strategy has yielded significant growth, including a 69% quarter-over-quarter revenue increase reported in late 2025. Amesite competes directly with established healthcare IT providers such as PointClickCare, Axxess Home Health, Tebra, and NextGen Healthcare, positioning itself as a high-efficiency, AI-native alternative that can either seamlessly integrate with or entirely replace legacy infrastructure. The company is led by Founder and CEO Dr. Ann Marie Sastry, a prominent technology entrepreneur and former tenured engineering professor at the University of Michigan who previously founded Sakti3, which was acquired by Dyson for $90 million. The executive team includes Sarah Berman as Principal Financial and Accounting Officer and Brandon Owens as Vice President of Sales, who oversees the company’s aggressive expansion into home health and hospice sectors. Amesite’s Board of Directors features high-pedigree leadership, including Dr. Gilbert Omenn, a former Amgen director, and John Losh, the former CFO of General Motors and Cardinal Health. Notable institutional backing includes positions from Kovitz Investment Group, Geode Capital Management, and Renaissance Technologies, reflecting a sophisticated investor base focused on the company’s pivot toward AI-integrated healthcare infrastructure.